Patents by Inventor Joseph Vetro

Joseph Vetro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Controlled-release peptide compositions and uses thereof
    Patent number: 10945962
    Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: March 16, 2021
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Joseph A. Vetro, Sam D. Sanderson
  • CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES THEREOF
    Publication number: 20190083408
    Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.
    Type: Application
    Filed: December 4, 2018
    Publication date: March 21, 2019
    Inventors: Joseph A. Vetro, Sam D. Sanderson
  • Controlled-release peptide compositions and uses thereof
    Patent number: 10220002
    Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: March 5, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Joseph A. Vetro, Sam D. Sanderson
  • Polyplexes of hydrophobically-modified siRNA for delivery of siRNA
    Patent number: 9320814
    Abstract: The present invention provides compositions and methods for delivering nucleic acid molecules to a cell.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: April 26, 2016
    Assignee: Board of Regents of the University of Nebraska
    Inventor: Joseph A. Vetro
  • CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES THEREOF
    Publication number: 20140314839
    Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 23, 2014
    Inventors: Joseph A. Vetro, Sam D. Sanderson
  • Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof
    Publication number: 20050032221
    Abstract: Inhibitors of type 2 methionine aminopeptidases (“MetAP2”), specifically dominant negative variants of MetAP2, both polypeptides and encoding polynucleotides, are provided. Also provided are methods of treating subjects suffering from cancer, diseases mediated by the immune system or opportunistic infections using inhibitors of MetAP2. Also provided are high through put screens and assays to detect and identify inhibitors of MetAP2 and downstream effectors of MetAP2.
    Type: Application
    Filed: November 13, 2003
    Publication date: February 10, 2005
    Inventors: Yie-Hwa Chang, William Micka, Joseph Vetro
  • Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof
    Publication number: 20020182701
    Abstract: Inhibitors of type 2 methionine aminopeptidases (“MetAP2”), specifically dominant negative variants of MetAP2, both polypeptides and encoding polynucleotides, are provided. Also provided are methods of treating subjects suffering from cancer, diseases mediated by the immune system or opportunistic infections using inhibitors of MetAP2. Also provided are high through put screens and assays to detect and identify inhibitors of MetAP2 and downstream effectors of MetAP2.
    Type: Application
    Filed: August 30, 2001
    Publication date: December 5, 2002
    Applicant: Saint Louis University
    Inventors: Yie-Hwa Chang, William S. Micka, Joseph A. Vetro